Navigation Links
Pharmacopeia Announces Third Quarter 2007 Financial Results
Date:11/1/2007

ut are not limited to, statements about the successful implementation of Pharmacopeia's strategic plans, Pharmacopeia's plans to develop PS433540, a product candidate from its DARA program, Pharmacopeia's Phase 2 and Phase 1 clinical studies with respect to PS433540, including timing and expected outcomes of such studies, Pharmacopeia's plans to develop PS178990, a product candidate from its SARM program, Pharmacopeia's Phase 1 clinical studies with respect to PS178990, including timing and expected outcomes of such studies, Pharmacopeia's estimates of the market opportunities for its product candidates, including PS433540 and PS178990, Pharmacopeia's ability to successfully perform under its collaborations with Bristol-Myers Squibb, Cephalon, GlaxoSmithKline, Organon and Wyeth, Pharmacopeia's ability to build its pipeline of novel drug candidates through its own internally-funded drug discovery programs, third party collaborations and in-licensing, Pharmacopeia's ability to raise additional capital, Pharmacopeia's expectations concerning the development priorities of its collaborators, their ability to successfully develop compounds and its receipt of milestones and royalties from the collaborations, Pharmacopeia's anticipated operating results, financial condition, liquidity and capital resources, Pharmacopeia's expectations concerning the legal protections afforded by U.S. and international patent law, Pharmacopeia's ability to pursue the development of new compounds and other business matters without infringing the patent rights of others, additional competition, and changes in economic conditions.

Further information about these and other relevant risks and uncertainties may be found in Pharmacopeia's Reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Pharmacopeia urges you to carefully review and consider the disclosures found in its filings which are available in the SEC EDGAR database at

SOURCE Pharmacopeia
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Pharmacopeia Announces Positive Results from Initial DARA Clinical Trial
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Sygnis Pharma AG announces date for presentation of clinical results
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... The following is being released by ... The Green Park Collaborative (GPC) will bring together ... medical device and pharmaceutical companies, as well as ... 2015 at its first ever workshop on the ... Participants will discuss study designs to evaluate weight ...
(Date:10/17/2014)... NORWALK, Conn. , Oct. 17, 2014  UBM ... leading online community for endocrinologists and other clinicians who ... offers comprehensive coverage on effective use of insulin ... will eventually require insulin replacement therapy – ... up for the progressive decline in the function of ...
(Date:10/17/2014)... 2014  Ameritox SM , the nation,s leader in ... Thomas Smith , M.D., as Chief Medical Officer. In ... scientific resources for healthcare providers, patients and managed care ... at a variety of healthcare companies that have provided ... and behavioral health sides of Ameritox,s business. He most ...
Breaking Medicine Technology:Green Park Collaborative to Discuss Comparative Effectiveness and Value of Weight Loss Treatments 2Endocrinology Network Features Special Coverage on Effective Use of Insulin 2Endocrinology Network Features Special Coverage on Effective Use of Insulin 3Ameritox Appoints New Chief Medical Officer 2
... Generex Biotechnology Corporation ( www.generex.com ) (OTCBB: ... President & Chief Executive Officer, and Dr. Eric ... Antigen Express, Inc. ( www.antigenexpress.com ) will make ... 13th Annual Healthcare Conference.  The presentation will take ...
... CITY, Calif., Sept. 7, 2011 Codexis, Inc. ... the company will be participating in the following ... ConferenceDate: Thursday, September 15, 2011 (Company presentation)Time: 8:00 ... of Financial Planning & Analysis A webcast and ...
Cached Medicine Technology:Generex to Present at the Rodman & Renshaw 13th Annual Healthcare Conference 2Generex to Present at the Rodman & Renshaw 13th Annual Healthcare Conference 3
(Date:10/20/2014)... OH (PRWEB) October 20, 2014 Women’s ... Specialists in Obstetrics & Gynecology of Columbus, Inc., A ... women’s healthcare services to more than 100,000 patients annually. ... though all ages and stages of a women’s life. ... office locations in Westerville and Dublin. , Dr. ...
(Date:10/20/2014)... hc1.com today announced the launch ... that enables healthcare organizations of all sizes to ... relationship management (“CRM”) solution. , Designed from the ... the healthcare industry, the hc1 Healthcare Relationship Cloud™ ... by combining healthcare CRM, HIPAA-compliant collaboration, and real-time ...
(Date:10/20/2014)... CA (PRWEB) October 20, 2014 JZ ... expertise, nutritional coaching, corporate wellness programming, authorship, international lecturing ... is excited to announce the release of the JZ ... After many years of coaching thousands of individuals on ... tracking app that does not require calorie counting or ...
(Date:10/20/2014)... Principle Business Enterprises, a family owned ... top-of-the-line absorbent products. The company has recently made ... brand, Tranquility® Premium Protection absorbent products. The company ... its packaging a new look, and is currently working ... the public. , The new website, developed with Thread ...
(Date:10/20/2014)... 20, 2014 Myoderm ... Assistant Director of their CentralSource service. ... the innovative turnkey drug sourcing, distribution, and management ... over 12 years of industry experience, in both ... the peak of their international success to help ...
Breaking Medicine News(10 mins):Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 2Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 3Health News:Healthcare Relationship Management (HRM) Leader hc1.com® Launches hc1® Quick Start™ 2Health News:JZ Fitness Nutrition App Launches on iTunes 2Health News:JZ Fitness Nutrition App Launches on iTunes 3Health News:Tranquility® Premium Protection Incontinence Products Releases New Logo and Website 2Health News:Myoderm Hires Matthew Voicheck to Lead Turnkey Drug Sourcing Service 2
... , , CHICAGO, Sept. ... by House Majority Leader Steny Hoyer (D-MD) - for recognizing the ... the overall health care reform bill currently under consideration. Over ... Democrats and Republicans across the country talking with constituents at town ...
... , , , ... Supermarkets are helping customers stay healthy and well by once ... period will start September 17 and run through November 1 ... doctor-administered vaccines. , , (Logo: http://www.newscom.com/cgi-bin/prnh/20030421/STATERLOGO ...
... , , , JACKSONVILLE, ... taking place Friday, Sept. 11, 2009, Wounded Warrior Project (WWP) and ... revenues generated from global trades made on that day. , , ... was created while Cantor Fitzgerald rebuilt following the World Trade Center attacks ...
... , , FARMINGDALE, N.Y., ... a developer of minimally invasive ultrasonic medical device technology, which ... worldwide for other acute health conditions, today announced the restructuring ... business units have been created; one for sales and service ...
... COLO Research published in the September 2009 issue of ... an individual,s quality of life prior to treatment can help ... cell lung cancer (NSCLC). For those with advanced stage ... months, with approximately one-third of patients surviving past the one ...
... are developing computer models to comb through thousands of ... claims data to automatically classify them based on specific ... the most important causes of injuries so that efforts ... in society," said Mark Lehto, an associate professor in ...
Cached Medicine News:Health News:Statement from the American College of Surgeons Regarding Growing Democrat Support for Medical Liability Reform to be Included in Health Care Reform 2Health News:Stater Bros. Helps Customers Fight the Flu 2Health News:Wounded Warrior Project to Participate in BGC Partners Annual Charity Day 2Health News:Misonix Restructures and Expands Sales Organization in Europe 2Health News:Misonix Restructures and Expands Sales Organization in Europe 3Health News:Misonix Restructures and Expands Sales Organization in Europe 4Health News:New computer models aim to classify, help reduce injury accidents 2
ENA Screen EIA Auto-Immune Markers 012-MDKES1 Extractable Nuclear Antigens...
Anti-PR3 EIA Auto-Immune Markers 013-PR3-48 Proteinase...
... can be viewed immediately, making procedures more efficient. ... the images are digital, they can be used ... electronic filing. The CR-DGi combines the power ... use. It's the latest advance from Canon, the ...
...
Medicine Products: